Drug-drug plasma protein binding interactions of ivacaftor
Elena K Schneider, Johnny X Huang, Vincenzo Carbone, Mark Baker, Mohammad AK Azad, Matthew A Cooper, Jian Li, Tony Velkov
JOURNAL OF MOLECULAR RECOGNITION | WILEY | Published : 2015
Ivacaftor is a novel cystic fibrosis (CF) transmembrane conductance regulator (CFTR) potentiator that improves the pulmonary function for patients with CF bearing a G551D CFTR-protein mutation. Because ivacaftor is highly bound (>97%) to plasma proteins, there is the strong possibility that co-administered CF drugs may compete for the same plasma protein binding sites and impact the free drug concentration. This, in turn, could lead to drastic changes in the in vivo efficacy of ivacaftor and therapeutic outcomes. This biochemical study compares the binding affinity of ivacaftor and co-administered CF drugs for human serum albumin (HSA) and α1 -acid glycoprotein (AGP) using surface plasmon re..View full abstract
T. V., J. L., M. B., and M. C. are supported by the Australian National Health and Medical Research Council (NHMRC). M. C. is an NHMRC Australia Fellow. J. L. is an Australian NHMRC Senior Research Fellow. T. V. is an Australian NHMRC Industry Career Development Research Fellow.